Temporal Readiness Analysis scores clinical trial protocols on a 0–40 scale — quantifying the risk that measurement timing misaligns with the biology you're trying to measure. Informed by a 275,000-trial retrospective analysis. Methods paper in preparation.
Most protocols set measurement timepoints based on convention — patient visit schedules, historical precedent, operational convenience. Not biology. When measurements miss the mechanistic window, trials generate data that can't distinguish a failed drug from a failed design.
Excellent translational teams already think about measurement timing intuitively. TRS makes this evaluation systematic, reproducible, and benchmarked — ensuring that institutional knowledge doesn't walk out the door when team members rotate.
Two oncology trials from our retrospective database. One succeeded with strong temporal design. One failed with identifiable gaps.
Early immune activation measured within the first week. Multi-scale coverage from cellular signaling through imaging. Biomarker velocity tracked monthly. Individual patient trajectories modeled.
Single endpoint at Week 12 with no early mechanistic data. No biomarker velocity tracking. Group-level analysis only. A TRS assessment would have identified specific low-cost additions.
See detailed evidence, methodology, and full indication-level data →
Answer a structured questionnaire about your study's measurement schedule — no protocol submission required. Receive a scored assessment with specific, costed recommendations. Delivered in two weeks.
Your protocol scored on a 0–40 scale across four temporal design components. Benchmarked against your indication and phase from the 275K-trial retrospective database.
Specific temporal gaps identified — missing mechanistic windows, insufficient sampling density, unresolved rate-of-change — with risk estimates based on retrospective associations in the database.
Concrete recommendations prioritized by impact-per-dollar. Full-protocol engagements include stepwise triage: Tier 1 (zero additional patient burden), Tier 2 (moderate), and Tier 3 (new visit windows) — so you implement only what fits your operational constraints.
Location-adjusted cost estimates for every recommendation. Per-patient incremental cost as a percentage of your existing execution budget, with estimated failure-cost-avoidance projections.
De-risk Phase 2 go/no-go decisions with quantitative temporal design evidence before committing enrollment budget.
First Phase 2 trial is often make-or-break. A TRS assessment costs less than one week of enrollment delay — and identifies the design flaws that cause preventable failures.
Design multi-scale measurement cascades that generate interpretable mechanism-of-action data, not just endpoint readouts.
Sign up and we'll reach out within 48 hours to discuss your program and determine which assessment pathway fits best.
Temporal Readiness Analysis is a product of Scientari LLC, based in Encinitas, California. Our methodology is grounded in established optimization frameworks (Design of Experiments, Response Surface Methodology) applied to biological timescale design.